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Abstract
Background: Huntington's disease (HD) occurs worldwide with prevalence varying from 0.1 to 10 /100,000 depending of  
the ethnic origin. Since no data is available in the Maghreb population, the aim of  this study is to describe clinical and genetic 
characteristics of  Huntington patients of  Moroccan origin.
Methods: Clinical and genetics data of  21 consecutive patients recruited from 2009 to 2014 from the outpatient clinic of  
six medical centers were analyzed. Statistical analysis was performed using descriptive statistics.
Results: Twenty one patients from 17 families were diagnosed positive for the IT15 gene CAG expansion. Clinical symp-
toms were predominantly motor (19/21). Twelve patients had psychiatric and behavioral disorders, and 11 patients had 
cognitive disorders essentially of  memory impairment. Analysis of  genetic results showed that 5 patients had reduced pen-
etrant (RP) alleles and 16 had fully penetrant (FP) alleles. The mean CAG repeat length in patients with RP alleles was 38.4 
± 0.54, and 45.37 ± 8.30 in FP alleles. The age of  onset and the size of  the CAG repeat length showed significant inverse 
correlation (p <0.001, r = -0.754). 
Conclusion: Clinical and genetic data of  Moroccan patients are similar to those of  Caucasian populations previously re-
ported in the literature. 
Keywords: Huntington disease/diagnosis, Huntington disease/epidemiology, Huntington disease/genetics, Trinucleotide 
repeat expansion
DOI: http://dx.doi.org/10.4314/ahs.v15i4.23
Cite as: Bouhouche A, Regragui W, Lamghari H, Khaldi K, Birouk N, Lytim S, et al. Clinical and genetic data of  Huntington disease in 
Moroccan patients. Afri Health Sci. 2015;15(4):1232-8. http://dx.doi.org/10.4314/ahs.v15i4.23
Introduction
Huntington’s disease (HD) is a rare neurodegenerative 
genetic disease, characterized by generalized chorea, 
dementia, and psychiatric disorders. HD is transmitted 
as an autosomal dominant trait; children of  an affect-
ed person have a 50% risk of  inheriting the disease. It 
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is caused by CAG triplet repeat expansions in exon 1 
of  the Huntingtin gene (IT15) located on chromosome 
4p16.31,2. Mutant alleles produce a sequence of  36 or 
more glutamine amino acid in Huntingtin protein which 
results in a selective neural cell death at the level of  the 
basal ganglia and cerebral cortex3. The onset of  clinical 
symptoms varies markedly, usually occurring between 
the ages of  35 and 55 years, however the disease can 
manifest at younger age before 14 years or much later 
after the age of  80. The age of  onset is inversely corre-
lated with CAG-repeat length, which accounts for 50 to 
70% of  the variance. Additional genetic and environ-
mental factors seem to modulate the course and the age 
at onset of  the disease4,5,6. HD is incurable with death 
occurring on average 16 years after disease onset7,8.
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Worldwide prevalence of  HD is 2.71 per 100,000, but 
varies greatly with ethnic origin. High prevalence is seen 
in populations of  Western European descent with 5.7 
per 100,0009 and much lower prevalence are seen in 
Japan, China, Finland, and Africa with about one per 
million people10,11,12,13. The highest prevalence has been 
reported in an isolated population of  Venezuela called 
Lake Maracaibo with up to 700 per 100,000 inhabitants, 
30% of  them have been identified as homozygous for 
the mutant allele14. Little is known on people of  Arabic 
origin; the few available studies concerned some coun-
tries from the Middle East with a prevalence rate of  3-4 
per 100,000 inhabitants15.
Huntington's disease was one of  the first hereditary 
neurological diseases for which genetic testing was 
made possible in 1993. However, up to date there is 
no publication in the literature reporting patients from 
North African origin. This present study is the first re-
port of  clinical and genetic data characteristics of  Hun-
tington patients in Morocco.
Patients and methods
During the period 2009 to June 2014, 21 HD patients 
belonging to 17 unrelated families were recruited 
consecutively from the outpatient clinic of  six medi-
cal centers in the province of  Rabat-Salé (Morocco); 
the majority of  them were seen in the Department of  
Neurology of  Hospital of  Spécialités. The 7 related 
patients belonged to 3 families, a brother and sister, a 
father and son, and father and 2 children respectively. 
In the absence of  a multidisciplinary counseling com-
mittee in Morocco, this study was conducted as part of  
a research project; and written informed consent was 
obtained from all subjects. The study was approved by 
the biomedical research ethics committee of  the Med-
ical School of  Rabat (CERB). Clinical evaluation was 
based on a questionnaire including motor symptoms 
(chorea, bradykinesia, tremor, dysarthria and dyspha-
gia) and cognitive and psychiatric symptoms (memory 
deficit, loss of  motivation, concentration problems, dif-
ficulty in managing kitchen utensils, computer, dress-
ing, taking shower, mood problem, insomnia, episode 
of  crying, loss of  smiling, …etc). Genomic DNA was 
extracted from peripheral blood leukocytes using Iso-
late II Genomic DNA kit from Bioline. The CAG re-
peat length was determined as reported by Teo CR et 
al.16. Briefly, 50 ng genomic DNA was amplified using 
fluorescently labeled primer (HDR-HEX) in a final vol-
ume of  25µl. One microliter of  each PCR product was 
mixed with 0.5μL of  the GeneScan 500HD ROX size 
standard and 9 μL of  HiDi Formamide (Applied Bio-
systems). The mixtures were subjected to capillary elec-
trophoresis on a 310 Genetic Analyzer (Applied Bio-
systems) for 45 min, and the electrophoretograms were 
analyzed with Genotyper software version 3.7 (Applied 
Biosystems). Alleles with CAG repeat size of  36 – 39 
was defined as reduced penetrant (RP) alleles and ≥ 40 
as fully penetrant (FP) alleles. Allele length less than 36 
was considered nonpathogenic17. Typical electrophore-
tograms of  normal and affected patients in the study 
population are shown in Fig. 1. Statistical analysis was 
conducted using descriptive statistics, the relationship 
between the repeat length and the age at onset was as-
sessed with the Bravais-Pearson correlation coefficient 
and statistical significance level was set at p < 0.05.
Results
Twenty one HD patients from 17 unrelated families 
were diagnosed positive for CAG repeat mutation, of  
which 8 (38%) were males. There were 4 (19%) spo-
radic cases and 17 (81%) familial-type HD patients 
belonging to 13 families. Eleven (65%) patients inher-
ited the mutation from the father and 6 (35%) from 
the mother. The mean age at examination was 44.90 ± 
10.09 years and the mean age of  onset of  the disease 
was 40.71 ± 8.65, including a patient with juvenile HD 
(starting at 5 years) and a patient with late-onset HD 
(starting at 64). Clinical symptoms were predominantly 
motor (19/21) mainly chorea, dysarthria and dysphagia. 
Twelve patients presented with psychiatric and behavio-
ral disorders particularly irritability, apathy and depres-
sion. Eleven patients had cognitive disorders essentially 
of  memory impairment, attention deficit and executive 
dysfunction.
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The genetic results showed that the mean number of  
pathological expanded CAG repeats was 43.8 ± 4.24 
(range, 38–75). The frequency distribution of  the CAG 
repeat size (Fig. 2) showed that the normal CAG re-
peats ranged from 9 to 23 repeats with a mode of  16 re-
peats, whereas the HD CAG repeats ranged from 38 to 
75 and the most frequent disease allele was 41 repeats. 
Fig. 3 shows the relationship between age of  onset and 
the CAG repeat size in affected subjects. The age of  
HD onset was inversely correlated with the size of  the 
expanded CAG repeats (r = -0.754, p<0.001), and the 
CAG repeat length accounts for up to 56% of  the vari-
ance in the age at onset (R2 = 0.56).
Of  the 21 HD patients studied, 16 had fully penetrant 
(FP) and 5, 4 of  them were women, had reduced pene-
trant (RP) CAG repeat alleles (Table 1). The mean CAG 
repeat size in the FP patient group was 45.5 ± 4.43 and 
was 38.4 ± 0.48 in the RP patient group. Although both 
groups had similar mean disease duration (4 years) their 
clinical presentation showed some differences. 
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Figure 1: Electrophoretogram of normal individual and HD patients. The graduate scale in the top 
indicates the length of the obtained fragment in bp. The size of the CAG repeat is determined from 
the main band with the highest intensity. A, B and C depict a normal individual, a reduced 
penetrant CAG repeat mutation carrier (RP) and a fully penetrant CAG repeat mutation carrier (FP) 
respectively. 
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Figure 2: Distribution of the normal and expanded CAG repeat alleles in  
Moroccan HD patients. 
 
 For patients of  both groups, the symptom of  onset 
remains largely chorea and motor signs were predom-
inant at age of  exam. However, psychiatric and behav-
ioral signs were more frequent in FP group than in RP 
group. 
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Figure 2: Distribution of the normal and expanded CAG repeat alleles in Moroccan HD patients. 
Figure 3: Inverse relationship between the age of onset of the disease and CAG repeat  
length. Diamonds represent expanded alleles and the diagonal line the regression curve. 
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Also, associated signs, more frequent in FP patients, 
have been seen only in one RP patient who had a dis-
ease duration of  10 years including dystonia, akinesia 
and swallowing disorder (Table 1). 
Late onset HD (> 60 years) was seen in one RP patient 
with CAG repeat size of  39 and who had only choreic 
movements after one year of  disease duration. Juvenile 
onset HD was seen in 1 FP patient with paternal in-
heritance, a 7 year old patient with onset in infancy (5 
years) who had 75 CAG repeats, and had the typical 
associated features of  rigidity, dyskinesia and dystonia. 
MRI showed in this patient atrophy of  the caudate nu-
cleus and putamen and dilatation of  the ventricles18.
 
Table 1: Clinical and genetic data of Moroccan patients with Huntington’s disease. 
 
Patients FP (N = 16) RP (N = 5) 
Mean CAG length 
Mean age at exam 
Mean age at onset 
Mean disease duration 
Sex (M:F) 
Positive HD family history 
Paternal inheritance 
Motor signs 










45.5 ± 4.43 
41.5 ± 9.50 
37.2 ± 7.71 














38.4 ± 0.48 
55.8 ± 5.44 
51.8 ± 6.64 














FP: Fully penetrant alleles, RP: Reduced penetrant alleles 
Discussion
Over a period of  6 years, 21 HD patients were positive 
for the IT15 gene CAG repeat recruited from different 
medical centers in the city of  Rabat that collects pa-
tients of  the Rabat-Salé province with 2 million people. 
By linear extrapolation, since many HD patients may 
not be receiving genetic testing particularly those ex-
amined by private physicians, the prevalence of  HD in 
Morocco with 34 million people could be estimated to 
about 1-4 per 100,000. For a right precise estimate of  
the prevalence, further epidemiological studies on Hun-
tington disease in Morocco are needed.
HD families of  Arab origin have been reported in 
Oman, Saudi Arabia, Syria, Lebanon, and Egypt. The 
prevalence rate in this Middle Eastern area was estimat-
ed to 3-4 per 100,00015. This is the first study of  HD 
in a Maghreb population composed of  Berbers and 
Arabs. HD was probably introduced in this population 
by several visitors in earlier time. Indeed, this region 
originally inhabited by Berbers, saw installation of  the 
Phoenicians (1200 BC) and various invasions including 
Romans, Vandals and Byzantines and the arrival of  the 
Arabs in the seventh century. The Ottoman Turks ar-
rived in 1550, succeeded the French people who took 
control of  Maghreb territories from 1830.
Four of  the twenty one patients (19%) with genetical-
ly confirmed HD did not have a positive family his-
tory. This incidence is similar to that reported in the 
literature, even in populations with low HD preva-
lence4,13,19,20. These sporadic cases are due to de novo 
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mutations resulting generally from expansion of  non-
penetrant alleles usually upon paternal transmission21. 
Therefore, genetic diagnosis of  patients with negative 
family history is relevant.
Genetic results showed that the expanded CAG repeat 
range was between 38 and 75 (mean = 43.8) and that of  
normal allele range was between 9 and 23. The distri-
bution of  the expanded CAG repeat and the significant 
correlation found for the relationship between the age 
of  onset and the CAG repeat expansion were similar to 
that for Caucasian population described previously4,13. 
However, the contribution of  CAG repeat length in our 
study accounts only for up to 56% of  the variance in 
the age at onset. This is lower than reported in some 
populations such as Venezuela with 85 %5 suggesting 
the existence of  other genetic and or environmental 
factors specific to Moroccan population.
Clinical results showed that HD patients with RP alleles 
had a moderate clinical presentation consisting of  mo-
tor and cognitive signs at age of  exam. However, the 
disease could became severe with behavioral and other 
associated signs such as dystonia and akinesia during 
the disease evolution as seen in one RP patient with 
10 years disease duration. HD patients with FP alleles 
manifest, in addition to motor and cognitive signs, psy-
chiatric and behavioral signs more frequently than RP 
patients. The most frequent associated signs in these 
patients were dystonia and sphincter disturbances. Ju-
venile HD with very large repeats is very rare and has 
been seen in our study in only one patient (1/16) with 
75 CAG repeats who had typical associated features of  
rigidity and dystonia. His father had 46 CAG repeats 
with an age at onset of  45 years and a moderate clinical 
phenotype, indicating an anticipation phenomenon.
Conclusion
This preliminary study of  HD patients in Morocco 
showed that clinical and genetic data are similar to pre-
vious reports. We also demonstrated the relevance of  
genetic testing of  patients with negative family histo-
ry for HD. The life-long management of  patients and 
families affected by HD is a major problem worldwide. 
However, since nuclear families are large in Moroccan 
population and the risk of  having several patients in the 
same family, we highlight in this paper the necessity to 
create a multidisciplinary council genetic unit in Mo-
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